国: シンガポール
言語: 英語
ソース: HSA (Health Sciences Authority)
Certolizumab pegol (CDP870)
UCB TRADING (SG) PTE. LTD.
L04AB05
200 mg/mL
INJECTION, SOLUTION
SUBCUTANEOUS
Prescription Only
Vetter Pharma-Fertigung GmbH & Co. KG
2013-11-08
1. NAME OF THE MEDICINAL PRODUCT CIMZIA (certolizumab pegol) 200 mg solution for injection in a pre-filled syringe. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Certolizumab pegol is a recombinant humanized antibody Fab' fragment that is expressed in an _Escherichia coli _bacterial expression system, subsequently purified and conjugated to polyethylene glycol (PEG). Each pre-filled syringe contains 200mg certolizumab pegol in one ml. For a full list of excipients, see section 7.1 3. PHARMACEUTICAL FORM Solution for injection in a pre-filled syringe. The pH of the solution is approximately 4.7. The solution is a clear to opalescent solution that is colorless to yellow, essentially free of visible particles. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS _RHEUMATOID ARTHRITIS_ CIMZIA, in combination with methotrexate (MTX), is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate, has been inadequate. CIMZIA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _4.2.1 _ _POSOLOGY_ 4.2.1.1 Rheumatoid arthritis _Loading dose _ The recommended loading dose of CIMZIA for adult patients with rheumatoid arthritis is 400 mg (given as 2 subcutaneous injections of 200 mg each) initially (week 0) and at weeks 2 and 4. _Maintenance dose_ After the loading dose, the recommended maintenance dose for adult patients with rheumatoid arthritis is 200mg every 2 weeks. Alternatively, CIMZIA 400 mg every 4 weeks can be considered wh 完全なドキュメントを読む